

JUN. 17. 2004 4:23PM

CHOATE HALL & STEWART 6172484000

NO. 558 P. 1

**CHOATE  
HALL &  
STEWART**

A PARTNERSHIP INCLUDING PROFESSIONAL CORPORATIONS

**OFFICIAL**

## Fax Transmittal Sheet

RECIPIENT	COMPANY	FAX	PHONE
Examiner D. Lukton	U.S. Patent and Trademark Office	1-703-872-9306	

FROM	C. Hunter Baker, M.D., Ph.D.	NUMBER OF PAGES	11
DATE	June 17, 2004	CLIENT NUMBER	2002941-0053
PHONE	(617) 248-5215	OPERATOR	TIME SENT

### COMMENTS

RETURN BY Inter-office Mail Hold for pick-up

This transmittal is intended only for the use of the individual or entity to which it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. If the reader of this transmittal is not the intended recipient, or the employee or agent responsible for delivering the transmittal to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately.

CHOATE, HALL & STEWART | 53 State Street, Boston MA 02109 | t 617 248 6000 f 617 248 4000 | www.choate.com

PAGE 1/11 \* RCVD AT 6/17/2004 4:29:03 PM [Eastern Daylight Time] \* SVR:USPTO-EFXXRF-1/8 \* DNIS:8729306 \* CSID:617 248 4000 \* DURATION (mm-ss):03-00

ATTORNEY'S DOCKET NUMBER: 2002941-0053

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

OFFICIAL

Applicant:	Bachovchin	Examiner:	Lukton, D.
Serial No.:	09/289,321	Art Unit:	1653
Filed:	April 9, 1999		
For:	MULTIVALENT COMPOUNDS FOR CROSSLINKING RECEPTORS AND USES THEREOF		

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**AMENDMENT**

This Amendment is submitted in response to the facsimile from Examiner Lukton dated June 13, 2004 in connection with the above-referenced Application. Applicant respectfully requests entrance of the following Amendment and consideration of the following Remarks.

Please amend the above-identified application as follows:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this Response.

Remarks begin on page 9 of this Response.